Harry P Erba, Pau Montesinos, Hee-Je Kim, Elżbieta Patkowska, Radovan Vrhovac, Pavel Žák, Po-Nan Wang, Tsvetomir Mitov, James Hanyok, Yasser Mostafa Kamel, Jaime E Connolly Rohrbach, Li Liu, Aziz Benzohra, Arnaud Lesegretain, Jorge Cortes, Alexander E Perl, Mikkael A Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Mark J Levis, Richard F Schlenk
BACKGROUND: Patients with acute myeloid leukaemia (AML) positive for internal tandem duplication (ITD) mutations of FLT3 have poor outcomes. Quizartinib, an oral, highly potent, selective, type 2 FLT3 inhibitor, plus chemotherapy showed antitumour activity with an acceptable safety profile in patients with FLT3-ITD-positive newly diagnosed AML. The aim of the study was to compare the effect of quizartinib versus placebo on overall survival in patients with FLT3-ITD-positive newly diagnosed AML aged 18-75 years...
May 13, 2023: Lancet